Nektar Turns Up The Heat On Partnering Talks For NKTR-181
The company reported positive Phase III efficacy data on the first-in-class mu-opioid agonist molecule designed to provide pain relief without the euphoria that leads to addiction with standard opioids.
You may also be interested in...
Public Company Edition: IPO performance has been mixed in 2019, but May has been the busiest month this year. Also, Insmed leads recent follow-on offerings and Dynavax restructures.
Stock soars yet again with a positive data update for immuno-oncology star NKTR-214, a better-than-expected fourth quarter and catalysts for other pipeline candidates coming soon.
Bristol-Myers Squibb expanded its collaboration with CytomX for $200m up front and up to $3.6bn in milestone fees. Also, Takeda spun out eight non-core molecules into a new joint venture and X-Chem executed two deals with Japanese partners, among other recent deals.